Prospects for pharmacotherapy of schizophrenia.
Pickar
D
D
Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, MD 20892, USA.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D003024:Clozapine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D007555:Isoxazoles; D010880:Piperidines; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D003024:Clozapine; D018967:Risperidone